Risk Factors Associated With Pirfenidone Discontinuation In Patients With Idiopathic Pulmonary Fibrosis In A Real-World Setting

被引：0
|
作者：
Cottin, V. [1 ]
Guenther, A. [2 ]
Albera, C. [3 ]
Tomassetti, S. [4 ]
Azuma, A. [5 ]
Bartley, K. [6 ]
Burgess, T. [6 ]
Odueyungbo, A. [6 ]
Kirchgaessler, K. -U. [7 ]
Maher, T. M. [8 ]
机构：
[1] Louis Pradel Hosp, Reference Ctr Rare Pulm Dis, Lyon, France
[2] Univ Hosp Giessen, Interstitial Lung Dis Clin, Giessen, Germany
[3] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
[4] GB Morgagni L Pierantoni Hosp, Dis Thorax, Forli, Forli Cesena, Italy
[5] Nippon Med Sch, Postgrad Sch Med, Pulm Med, Tokyo, Japan
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Roche, Basel, Switzerland
[8] Royal Brompton Hosp, Interstitial Lung Dis Unit, London, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5392
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, D.
    Jouneau, S.
    Bouzille, G.
    Polard, E.
    Osmont, M. N.
    Scailteux, L. M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 77 - 78
  • [2] Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients
    Fournier, Dorine
    Jouneau, Stephane
    Bouzille, Guillaume
    Polard, Elisabeth
    Osmont, Marie-Noëlle
    Scailteux, Lucie-Marie
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 76
  • [3] Factors associated with dose reduction of pirfenidone in patients with idiopathic pulmonary fibrosis: A study based on real-world clinical data
    Kim, Jiwon
    Chung, Chiwook
    Cho, Hyo Sin
    Kim, Ho Cheol
    [J]. PLOS ONE, 2023, 18 (02):
  • [4] Real-World Maintenance Strategies and Persistence with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    Lancaster, L. H.
    Burg, C. A.
    Haselkorn, T.
    Yang, M.
    Corral, M.
    Stauffer, J. L.
    Huggins, J. T.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] Pirfenidone In Idiopathic Pulmonary Fibrosis In The Real World
    Song, J.
    Park, J. -H.
    Heo, E.
    Kim, D.
    Chung, H. Hee Soon
    Lee, J-K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [6] Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
    Tzouvelekis, Argyrios
    Karampitsakos, Theodoros
    Ntolios, Paschalis
    Tzilas, Vasilios
    Bouros, Evangelos
    Markozannes, Evangelos
    Malliou, Ioanna
    Anagnostopoulos, Aris
    Granitsas, Andreas
    Steiropoulos, Paschalis
    Dimakou, Katerina
    Chrysikos, Serafeim
    Koulouris, Nikolaos
    Bouros, Demosthenes
    [J]. FRONTIERS IN MEDICINE, 2017, 4 : 1 - 1
  • [7] Characteristics of a Real-World Canadian Cohort of Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone
    Ryerson, C.
    Kolb, M. R. J.
    Cox, G. P.
    Shapera, S.
    Swigris, J. J.
    Fell, C. D.
    O'Brien, M.
    Yang, M.
    Cabalteja, C.
    Mendoza, O. Moran
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [8] Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort
    Durheim, Michael T.
    Bendstrup, Elisabeth
    Carlson, Lisa
    Sutinen, Eva M.
    Hyldgaard, Charlotte
    Kalafatis, Dimitrios
    Myllarniemi, Marjukka
    Skold, C. Magnus
    Sjaheim, Tone
    [J]. RESPIROLOGY, 2021, 26 (10) : 982 - 988
  • [9] Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study
    Tzouvelekis, Argyrios
    Ntolios, Paschalis
    Karampitsakos, Theodoros
    Tzilas, Vasilios
    Anevlavis, Stavros
    Bouros, Evangelos
    Steiropoulos, Paschalis
    Koulouris, Nikolaos
    Stratakos, Grigoris
    Froudarakis, Marios
    Bouros, Demosthenes
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 : 48 - 53
  • [10] Real World Experiences: Pirfenidone Is Well Tolerated In Patients With Idiopathic Pulmonary Fibrosis
    Chaudhuri, N.
    Leonard, C.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
12345